33rd Annual New Treatments in Chronic Liver Disease

Join us March 9-11, 2018 in La Jolla!

Join us March 9-11, 2018 in La Jolla!

New Treatments in Chronic Liver Disease will provide an update on commonly encountered problems in the treatment of liver disease.

About the Conference

About the Conference

Conference Location

Conference Location

Estancia La Jolla Hotel

9700 N Torrey Pines Road

La Jolla, California 92037

meritagecollection.com/estancialajolla/

Course Overview

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

Educational Objectives

After participating in this live activity, participants should be able to:

  • Understand the details of the AASLD guidelines for treatment of HCV using DAA’s in IFN-free regimens.
  • Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the    conditions.
  • Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
  • Discuss therapies for HCV including NS5A, protease and polymerase inhibitors.
  • Update the skills and management required for transplant hepatology.
  • Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
  • Discuss future treatment paradigms for HCV direct-acting antiviral drug.
  • Describe the diagnosis and treatment of PBC and PSC.
  • Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
  • Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
  • Review the management of complications beta-blocker therapy in ESLD.

Accreditation and Disclosures

Physicians

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.


Cultural and Linguistic Competency

This activity is in compliance with California Assembly Bill 1195, which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. A variety of resources are available that address cultural and linguistic competency, some of which can be found in the Cultural & Linguistic Competency Resource Guide.

Future Dates

Future Dates

34th Annual New Treatments in Chronic Liver Disease

March 8-10, 2019

Estancia Hotel, La Jolla, California

Event Details
Date Time
Fri, Mar 9th, 2018 - Sun, Mar 11th, 2018 12:30 PM - 11:45 AM